Endurance RP (HK:0575) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Regent Pacific Group has announced a key manufacturing and supply agreement for Senstend, a treatment for premature ejaculation, with its partner in China, paving the way for regulatory approval and a potential market of millions. The agreement, which could result in significant milestone payments and royalties for Regent Pacific, is expected to expedite the New Drug Application process with China’s National Medical Products Administration. With a strong distribution network through Wanbang Biopharmaceutical, the company anticipates commercial success in China’s vast healthcare market.
For further insights into HK:0575 stock, check out TipRanks’ Stock Analysis page.
